Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer

The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second‐line treatment for metastatic colorectal cancer. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwasa, Satoru, Muro, Kei, Morita, Satoshi, Park, Young Suk, Nakamura, Masato, Kotaka, Masahito, Nishina, Tomohiro, Matsuoka, Hiroshi, Ahn, Joong Bae, Lee, Keun‐Wook, Hong, Yong Sang, Han, Sae Won, Cho, Sang‐Hee, Zhang, Dong‐Sheng, Fang, Wei‐Jia, Bai, Li, Yuan, Xiang‐Lin, Yuan, Ying, Yamada, Yasuhide, Sakamoto, Junichi, Kim, Tae Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586680/
https://www.ncbi.nlm.nih.gov/pubmed/34327766
http://dx.doi.org/10.1111/cas.15092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586680/
https://www.ncbi.nlm.nih.gov/pubmed/34327766
http://dx.doi.org/10.1111/cas.15092

Ejemplares similares